Finnish firm Leiras Oy, part of Germany's Schering AG and manufacturerof the number one Finnish pharmaceutical export, the contraceptive Mirena, is set to offer pharmaceutical and biotechnology companies its proprietary polymer-based drug delivery technology DELVIVO.
International biotechnology and pharmaceutical companies that require a fresh, long-term method of administration for active pharmaceutical ingredients are regarded as potential users for this system. Through use of DELVIVO, active ingredients of drugs can be released over a long period of time, at an even rate, into the body. This technology can be used for both short and long-term drug therapy requiring sustained, constant drug delivery.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze